.png){kind=icon}
返回
.png){kind=icon}
.png){kind=icon}
摘要
En 中文
Efgartigimod (efgartigimod alfa-fcab, Vyvgart((TM))) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. Intravenous efgartigimod has also been evaluated for generalized myasthenia gravis in various other countries, with the agent subsequently approved in Japan in January 2022 for generalized myasthenia gravis patients regardless of antibody status and in preregistration stage in the EU. Several clinical studies of intravenous and subcutaneous formulation of efgartigimod are also being investigated for other autoimmune diseases including bullous pemphigoid, chronic inflammatory demyelinating polyradiculoneuropathy, immune thrombocytopenia, autoimmune myositis and pemphigus. This article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
暂无机构信息
引用论文
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans新生儿Fc受体拮抗剂efgartigimod安全且可持续地降低人类的igg.png)
OAAI
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏β-nicotinamide mononucleotide rescues the quality of aged oocyte and improves subsequent embryo development in pigs.png)
PLOS ONEOAAI
PLOS ONEIF0
OAAI分享收藏Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisFcRn拮抗剂efgartigimod在全身性重症肌无力中的随机2期研究NEUROLOGY
OAAI
NEUROLOGYIF8.5
OAAI分享收藏Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia新型FcRn拮抗剂efgartigimod在成人原发性免疫性血小板减少症患者中的2期研究OAAI
OAAI分享收藏NEUROMUSCULAR DISEASE Getting specific: targeting Fc receptors in myasthenia gravisNATURE REVIEWS NEUROLOGY
NATURE REVIEWS NEUROLOGYIF33.1
PREAI
分享收藏 没有更多内容
没有更多内容